{
    "organizations": [],
    "uuid": "a3ef6438074598e48df8f796c91af015ff01d080",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-celgene-says-otezla-phase-ii-data/brief-celgene-says-otezla-phase-ii-data-showed-clinically-meaningful-improvements-in-active-ulcerative-colitis-patients-idUSFWN1Q5126",
    "ord_in_thread": 0,
    "title": "BRIEF-Celgene Says Otezla Phase II Data Showed Clinically Meaningful Improvements In Active Ulcerative Colitis Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Celgene Corp:\n* OTEZLA® (APREMILAST) PHASE II DATA SHOWED CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENTS WITH ACTIVE ULCERATIVE COLITIS\n* CELGENE CORP - ‍PHASE III PROGRAM WITH OTEZLA (APREMILAST) IN ULCERATIVE COLITIS EXPECTED TO BEGIN IN 2018​\n* CELGENE CORP - ‍PRIMARY ENDPOINT OF STUDY WAS TOTAL MAYO SCORE CLINICAL REMISSION AT WEEK 12 FOR 40 MG BID ARM​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-15T23:13:00.000+02:00",
    "crawled": "2018-02-16T16:53:16.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "celgene",
        "corp",
        "apremilast",
        "phase",
        "ii",
        "data",
        "showed",
        "clinically",
        "meaningful",
        "improvement",
        "patient",
        "active",
        "ulcerative",
        "colitis",
        "celgene",
        "corp",
        "iii",
        "program",
        "otezla",
        "apremilast",
        "ulcerative",
        "colitis",
        "expected",
        "begin",
        "celgene",
        "corp",
        "endpoint",
        "study",
        "total",
        "mayo",
        "score",
        "clinical",
        "remission",
        "week",
        "mg",
        "bid",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}